FMDV Specific Neutra™ Antibody Products

Product list

Accelerate Your Research and Development!

FMD remains one of the most economically devastating livestock diseases globally, requiring highly accurate and rapid diagnostic tools for effective control. Are you struggling to reliably differentiate natural infection from vaccination in endemic areas, or to precisely monitor vaccine efficacy across diverse serotypes? Creative Biolabs' Neutra™ Antibody Products deliver the validated, high-specificity reagents needed for pivotal studies in virology, vaccinology, and global disease eradication programs.

Contact our team to get an inquiry now!

Introduction of FMDV

FMDV, the highly contagious picornavirus (Aphthovirus), is the agent of Foot-and-Mouth Disease. It has a positive-sense, single-stranded RNA genome enclosed in a non-enveloped, icosahedral capsid, about 30nm in diameter.

The virus shows remarkable antigenic diversity across seven distinct serotypes: O, A, C, Asia 1, SAT 1, SAT 2, and SAT 3. Immunity to one serotype does not protect against the others, which mandates serotype-specific control and diagnostic measures.

Key Viral Protein Components

During replication, the FMDV polyprotein cleaves into structural proteins (SPs) and non-structural proteins (NSPs).

Structural Proteins (SPs): VP1, VP2, VP3, and VP4, form the capsid. The surface-exposed proteins contain major neutralizing epitopes, with VP1 being the principal B-cell epitope crucial for protective immunity.
Non-Structural Proteins (NSPs): Including L^pro, 2A-2C, and 3A-3D, these NSPs are associated with the replication machinery. Critically, NSPs are produced in large quantities only during natural infection, making them ideal diagnostic markers for detecting true infection.

Fig.1 Schematic of Immune cell dysfunction caused by foot-and-mouth disease virus infection. (OA Literature) Fig.1 Immune cell dysfunction caused by foot-and-mouth disease virus (FMDV) infection.¹

Antibodies Against FMDV

Creative Biolabs' Neutra™ Antibodies are strategically developed against critical FMDV antigens for superior specificity and performance in immunological applications.

Structural Protein (SP) Targeting Antibodies (Anti-VP1, Anti-VP2, Anti-VP3)

Targeting capsid proteins like VP1, these essential antibodies aid vaccine development and monitoring through two key functions:

Antigen Capture: Used in capture ELISAs to quantify FMDV antigen during vaccine production and ensure batch consistency.
Serological Assessment: Serotype-specific Anti-VP1 antibodies detect the humoral response from both vaccination and infection, serving as a rapid measure of protective immunity.

Non-Structural Protein (NSP) Targeting Antibodies (Anti-3ABC, Anti-3D)

These DIVA strategy reagents are critical because modern vaccines lack NSPs, making the presence of Anti-3ABC antibodies a reliable indicator of natural FMDV replication and true infection. NSP antibody applications include:

DIVA Assays: Key reagents in ELISAs to differentiate infected animals from vaccinated ones.
Surveillance: Monitoring populations in endemic or recovered FMD-free zones.
Vaccine QC: Confirming NSP absence in commercial vaccine preparations.

Why Choose Us?

Choosing Creative Biolabs' Neutra™ FMDV Antibodies means partnering with a supplier committed to quality, specificity, and global disease control standards.

Broad Serotype Coverage: We provide validated antibodies across the most significant serotypes (O, A, Asia 1, SATs), ensuring relevance to global outbreak strains.
DIVA Validation Excellence: Our Anti-NSP products, like the sensitive Anti-3ABC monoclonals, are rigorously validated against WOAH guidelines for high diagnostic specificity in livestock field samples.
Exceptional Lot Consistency: Produced under stringent QC standards, our Neutra™ antibodies guarantee high lot-to-lot consistency, vital for long-term surveillance and commercial kit manufacturing.
Optimal Application Performance: Each antibody is application-tested for ELISA, Western Blotting, and Immunohistochemistry (IHC), ensuring optimal performance across laboratory protocols.

FAQs

Q: What is the diagnostic difference between an Anti-3ABC (NSP) antibody and an Anti-VP1 (SP) antibody?

A: Anti-3ABC is essential for the DIVA strategy. As a non-structural protein, 3ABC is only produced during natural viral replication, meaning detecting Anti-3ABC confirms true infection. Conversely, Anti-VP1 targets the capsid and detects immune responses resulting from both infection and most commercial, NSP-depleted vaccines.

Q: What is the specificity profile regarding FMDV serotypes and non-FMDV pathogens?

A: Structural protein (SP) antibodies, such as Anti-VP1, are typically highly serotype-specific. Non-structural protein (NSP) antibodies, like Anti-3ABC, target conserved regions to offer broad reactivity across all FMDV serotypes while being rigorously tested to ensure no cross-reactivity with major non-FMDV bovine or swine pathogens.

Q: What are the primary applications for FMDV antibodies in disease control and research?

A: These reagents are suitable for diagnostic kit development (ELISA, Lateral Flow), research studies (Western Blotting, Immunofluorescence), and large-scale serosurveillance programs requiring rapid, high-throughput testing.

Q: Are polyclonal or monoclonal antibody formats available for FMDV targets?

A: Both formats are offered. Monoclonal antibodies (MAbs) against VP1 and 3ABC provide high specificity and consistency for kit production and precise epitope research. Polyclonal antibodies are available for applications that require broader recognition of FMDV epitopes.

Access the Creative Biolabs Edge – Request Your Quote Now

REFERENCE

Li, Kangli et al. "Virus-Host Interactions in Foot-and-Mouth Disease Virus Infection." Frontiers in immunology vol. 12 571509. 26 Feb. 2021, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2021.571509

Show More Close